Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...

Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, announced Thursday that it will lay off about 10% of its workforce. Moderna CEO ...

"Now we are an oncology company," Moderna CEO Stéphane Bancel told Insider.

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Has BridgeBio's business model worked? How are executives at Moderna dealing with the company's slump? Find out on the new episode of "The Readout LOUD." ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Dec 2 (Reuters) - Moderna Inc's (MRNA.O), opens new tab COVID-19 vaccine could be approved for emergency use within 24 to 72 hours after the U.S. health regulator's advisory committee meeting, Chief ...

Moderna is working on a stronger tool to fight the COVID-19 pandemic. However, officials say it will take time. The drugmaker says research is underway toward a one-dose, yearly booster to battle the ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...